Clinical Trial Update: Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of omalizumab (Xolair) for chronic urticaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Chronic Urticaria | Phase 2 | Status: COMPLETED